Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Опыт применения комплексного антибактериального и обезболивающего препарата на основе бактериофагов в гелевой форме у женщин, перенесших различные инструментальные и лечебно-диагностические манипуляции
Опыт применения комплексного антибактериального и обезболивающего препарата на основе бактериофагов в гелевой форме у женщин, перенесших различные инструментальные и лечебно-диагностические манипуляции
Васильев А.О., Сазонова Н.А., Мельников В.Д. и др. Опыт применения комплексного антибактериального и обезболивающего препарата на основе бактериофагов в гелевой форме у женщин, перенесших различные инструментальные и лечебно-диагностические манипуляции. Гинекология. 2020; 22 (3): 42–48.
DOI: 10.26442/20795696.2020.3.200199
DOI: 10.26442/20795696.2020.3.200199
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Во время распространения бактериальных инфекций с широкой лекарственной устойчивостью потенциал существующих антибактериальных препаратов значительно снижается. Медицинское сообщество ищет возможности рационального использования антибактериальных препаратов, разработки новых средств, а также использования альтернативного лечения данных инфекций.
Цель. Оценка эффективности применения комплексного антибактериального и обезболивающего препарата на основе бактериофагов в гелевой форме при выполнении различных инструментальных исследований и лечебно-диагностических процедур с целью минимизации риска инфекционных осложнений со стороны органов мочевыделительной системы.
Материалы и методы. В исследование включены 235 женщин в возрасте от 18 до 75 лет, проходивших лечение в ГБУЗ «ГКБ им. С.И. Спасокукоцкого», а также в клинике урологии ФГБОУ ВО «МГМСУ им. А.И. Евдокимова» в период с сентября 2019 по январь 2020 г. Всем пациенткам основной группы (n=120) в ходе манипуляции применен разработанный препарат на основе бактериофагов, в контрольной (n=115) – гель для местного применения на основе хлоргексидина дигидрохлорида и лидокаина гидрохлорида. Всем пациенткам до манипуляции, а также спустя 10 дней проводился бактериологический анализ мочи на наличие микрофлоры. Оценка эффективности выполнялась на основании полученных лабораторных данных, а также по данным визуальной аналоговой шкалы выраженности болевого синдрома.
Результаты. Ни у одной из пациенток основной группы не отмечено непереносимости, побочных явлений и аллергических реакций разработанного препарата на основе бактериофагов. Бактериологический анализ мочи, полученной до проведения манипуляции в обеих группах, показал отсутствие клинически значимых титров патогенных бактерий, в то время как спустя 1 нед после манипуляции количество титров патогенных бактерий (104 и более) значительно больше в контрольной группе (p>0,04). У пациенток основной группы частота развития дизурических явлений была ниже по сравнению с контрольной группой (p<0,05).
Заключение. Проведенное исследование показало хорошую переносимость разработанного препарата и его клиническую эффективность в снижении числа симптоматической бактериурии; выраженность болевого синдрома после перенесенной манипуляции была также сравнительно ниже в основной группе пациенток. Проведение мультицентровых исследований с включением большего числа пациентов в перспективе позволит уменьшить экономические затраты, связанные с лечением пациентов, за счет сокращения числа случаев внутрибольничной инфекции и снижения послеоперационного кой̆ко-дня.
Ключевые слова: бактериофаги, антибиотикорезистентность, инфекции нижних мочевыводящих путей, фаготерапия
Aim. The objective of this study was to evaluate the effectiveness of the use of a complex antibacterial and analgesic drug based on bacteriophages in gel form during various instrumental studies and diagnostic procedures in order to minimize the risk of the urinary system infections complications.
Materials and methods. The study included 235 women aged 18 to 75 years who underwent treatment at the Moscow State Clinical Hospital named after Spasokukotsky and in the clinic of urology of Moscow State University of Medicine and Dentistry from September 2019 to January 2020. During the manipulation, all patients of the main group (n=120) used a developed preparation based on bacteriophages, and in the control group (n=115), a topical gel based on chlorhexidine dihydrochloride and lidocaine hydrochloride was used. All patients before the manipulation, as well as 10 days after the manipulation, underwent bacteriological analysis of urine. Efficiency assessment was carried out on the basis of laboratory data obtained, as well as according to the visual analogue scale of the pain syndrome severity.
Results. None of the patients in the main group showed intolerance, side effects and allergic reactions of the developed drug based on bacteriophages. Bacteriological analysis of urine received before manipulation in both groups showed the absence of clinically significant titers of pathogenic bacteria, while 1 week after manipulation the number of titers of pathogenic bacteria (≥104) was significantly higher in the control group (p>0.04). In patients of the main group, the incidence of dysuria was lower compared with the control group (p<0.05).
Conclusion. The study showed good tolerance of the developed drug and its clinical effectiveness in reducing the number of symptomatic bacteriuria; severity of pain after undergoing manipulation was relatively lower in the main group of patients. Conducting multicenter studies with the inclusion of a larger number of patients in the future will reduce the economic costs associated with treating patients by reducing the number of cases of nosocomial infections and reducing postoperative time spent by patients in the hospital.
Key words: bacteriophages, antibiotic resistance, urinary tract infections, bacteriophage therapy.
Цель. Оценка эффективности применения комплексного антибактериального и обезболивающего препарата на основе бактериофагов в гелевой форме при выполнении различных инструментальных исследований и лечебно-диагностических процедур с целью минимизации риска инфекционных осложнений со стороны органов мочевыделительной системы.
Материалы и методы. В исследование включены 235 женщин в возрасте от 18 до 75 лет, проходивших лечение в ГБУЗ «ГКБ им. С.И. Спасокукоцкого», а также в клинике урологии ФГБОУ ВО «МГМСУ им. А.И. Евдокимова» в период с сентября 2019 по январь 2020 г. Всем пациенткам основной группы (n=120) в ходе манипуляции применен разработанный препарат на основе бактериофагов, в контрольной (n=115) – гель для местного применения на основе хлоргексидина дигидрохлорида и лидокаина гидрохлорида. Всем пациенткам до манипуляции, а также спустя 10 дней проводился бактериологический анализ мочи на наличие микрофлоры. Оценка эффективности выполнялась на основании полученных лабораторных данных, а также по данным визуальной аналоговой шкалы выраженности болевого синдрома.
Результаты. Ни у одной из пациенток основной группы не отмечено непереносимости, побочных явлений и аллергических реакций разработанного препарата на основе бактериофагов. Бактериологический анализ мочи, полученной до проведения манипуляции в обеих группах, показал отсутствие клинически значимых титров патогенных бактерий, в то время как спустя 1 нед после манипуляции количество титров патогенных бактерий (104 и более) значительно больше в контрольной группе (p>0,04). У пациенток основной группы частота развития дизурических явлений была ниже по сравнению с контрольной группой (p<0,05).
Заключение. Проведенное исследование показало хорошую переносимость разработанного препарата и его клиническую эффективность в снижении числа симптоматической бактериурии; выраженность болевого синдрома после перенесенной манипуляции была также сравнительно ниже в основной группе пациенток. Проведение мультицентровых исследований с включением большего числа пациентов в перспективе позволит уменьшить экономические затраты, связанные с лечением пациентов, за счет сокращения числа случаев внутрибольничной инфекции и снижения послеоперационного кой̆ко-дня.
Ключевые слова: бактериофаги, антибиотикорезистентность, инфекции нижних мочевыводящих путей, фаготерапия
________________________________________________
Aim. The objective of this study was to evaluate the effectiveness of the use of a complex antibacterial and analgesic drug based on bacteriophages in gel form during various instrumental studies and diagnostic procedures in order to minimize the risk of the urinary system infections complications.
Materials and methods. The study included 235 women aged 18 to 75 years who underwent treatment at the Moscow State Clinical Hospital named after Spasokukotsky and in the clinic of urology of Moscow State University of Medicine and Dentistry from September 2019 to January 2020. During the manipulation, all patients of the main group (n=120) used a developed preparation based on bacteriophages, and in the control group (n=115), a topical gel based on chlorhexidine dihydrochloride and lidocaine hydrochloride was used. All patients before the manipulation, as well as 10 days after the manipulation, underwent bacteriological analysis of urine. Efficiency assessment was carried out on the basis of laboratory data obtained, as well as according to the visual analogue scale of the pain syndrome severity.
Results. None of the patients in the main group showed intolerance, side effects and allergic reactions of the developed drug based on bacteriophages. Bacteriological analysis of urine received before manipulation in both groups showed the absence of clinically significant titers of pathogenic bacteria, while 1 week after manipulation the number of titers of pathogenic bacteria (≥104) was significantly higher in the control group (p>0.04). In patients of the main group, the incidence of dysuria was lower compared with the control group (p<0.05).
Conclusion. The study showed good tolerance of the developed drug and its clinical effectiveness in reducing the number of symptomatic bacteriuria; severity of pain after undergoing manipulation was relatively lower in the main group of patients. Conducting multicenter studies with the inclusion of a larger number of patients in the future will reduce the economic costs associated with treating patients by reducing the number of cases of nosocomial infections and reducing postoperative time spent by patients in the hospital.
Key words: bacteriophages, antibiotic resistance, urinary tract infections, bacteriophage therapy.
Полный текст
Список литературы
1. Колонтарев К.Б. Обзор клинических рекомендаций по лечению острой неосложненной инфекции нижних мочевых путей. Эффективная фармакотерапия. 2015; 3: 6–14.
[Kolontarev K.B. Obzor klinicheskikh rekomendatsii po lecheniiu ostroi neoslozhnennoi infektsii nizhnikh mochevykh putei. Effektivnaia farmakoterapiia. 2015; 3: 6–14 (in Russian).]
2. Arshad M, Seed PC. Urinary tract infections in the infant. Clin Perinatol 2015; 42 (1): 17–28.
3. Stamm WE, Norrby SR. Urinary tract infections: disease panorama and challenges. J Infect Dis 2001; 183 (Suppl 1.):S1–4.
4. Лоран О.Б., Синякова Л.А., Косова И.В. Рецидивирующие инфекции мочевых путей. Алгоритм диагностики и лечения. М.: МИА, 2008.
[Laurent O.B., Sinyakova L.A., Kosova I.V. Recurrent urinary tract infections. Algorithm for diagnosis and treatment. Moscow: MIA, 2008 (in Russian).]
5. Nappi RE, Palacios S. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric 2014; 17 (1): 3–9. DOI:10.3109/13697137.2013.871696
6. Santajit S, Indrawattana N. Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens. BioMed Res Int 2016; p. 1–8.
7. Эйдельштейн М.В., Сухорукова М.В., Склеенова Е.Ю. и др. Антибиотикорезистентность нозокомиальных штаммов Pseudomonas aeruginosa в стационарах России: результаты многоцентрового эпидемиологического исследования «Марафон» 2013–2014. Клин. микробиология и антимикробная химиотерапия. 2017; 19 (1): 37–41.
[Eidel'shtein M.V., Sukhorukova M.V., Skleenova E.Iu. et al. Antibiotikorezistentnost' nozokomial'nykh shtammov Pseudomonas aeruginosa v statsionarakh Rossii: rezul'taty mnogotsentrovogo epidemiologicheskogo issledovaniia "Marafon" 2013–2014. Klin. mikrobiologiia i antimikrobnaia khimioterapiia. 2017; 19 (1): 37–41 (in Russian).]
8. Kutateladze M, Adamia R. Bacteriophages as Potential New Therapeutics to Replace or Supplement Antibiotics. Trends Biotechnol 2010; 28: 591–5.
9. Miedzybrodzki R, Hoyle N, Zhvaniya F et al. Current Updates fr om the Long-standing Phage Research Centers in Georgia, Poland and Russia. In Bacteriophages; Harper, D., Abedon, S., Burrowes, B., Eds.; Springer: Cham, Switzerland, 2018; p. 1–31.
10. Antibiotic Resistance Threats in the United States; U.S. Department of Health and Human Services, CDC: Atlanta, GA, USA, 2019.
11. Ширяев А.А., Васильев А.О., Зайцев А.В. и др. Перспектива применения бактериофагов в урологической практике. Урология. 2019; 6: 131–6.
[Shiriaev A.A., Vasil'ev A.O., Zaitsev A.V. et al. Perspektiva primeneniia bakteriofagov v urologicheskoi praktike. Urologiia. 2019; 6: 131–6 (in Russian).]
12. Howell AB, Reed JD, Kreuger CG et al. A-type cranberry proanthocyanidins and uropathogenic bacterial anti- adhesion activity. Phytochemistry 2005; 66: 2281–91. DOI: 10.1016/j.phytochem.2005.05.022
13. Singh I, Gautam LK, Kaur IR. Effect of oral cranberry extract (standardized proanthocyanidin-A) in patients with recurrent UTI by pathogenic E. coli: a randomized placebo-controlled clinical research study. Int Urol Nephrol 2016; 48: 1379–86. DOI: 10.1007/s11255-016-1342-8
14. Vostalova J, Vidlar A, Simanek V et al. Are high proanthocyanidins key to Cranberry efficacy in the prevention of recurrent urinary tract infection? Phytother Res 2015; 29: 1559–67. DOI: 10.1002/ptr.5427
15. Naber KG. Efficacy and safety of the phytotherapeutic drug Canephron N in prevention and treatment of urogenital and gestational disease: review of clinical experience in Eastern Europe and Central Asia. Res Rep Urol 2013; 5: 39–46.
16. Miotla P, Wawrysiuk S, Naber K et al. Should we always use antibiotics after urodynamic studies in high-risk patients? Biomed Res Int 2018; 2018: 1607425. DOI: 10.1155/2018/1607425
17. Wagenlehner FM, Abramov-Sommariva D, Höller M, Steindl H et al. Non-Antibiotic Herbal Therapy (BNO 1045) versus antibiotic therapy (Fosfomycin Trometamol) for the treatment of acute lower uncomplicated urinary tract infections in women: a double-blind, parallel-group, randomized, multicentre non-inferiority phase III trial. Urol Int 2018; 101: 327–36. DOI: 10.1159/000493368
18. Stapleton AE. The vaginal microbiota and urinary tract infection. Microbiol Spectr 2016. DOI: 10.1128/microbiolspec.UTI-0025-2016
19. Beerepoot MA, ter Riet G, Nys S et al. Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in postmenopausal women. Arch Intern Med 2012; 172: 704–12. DOI: 10.1001/archinternmed.2012.777
20. Schwenger EM, Tejani AM, Loewen PS. Probiotics for Preventing Urinary Tract Infections in Adults and Children. Cochrane Database Syst Rev 2015; 12: CD008772. DOI: 10.1002/14651858.CD008772.pub2
21. Gupta V, Nag D, Garg P. Recurrent urinary tract infections in women: how promising is the use of probiotics? Indian J Med Microbiol 2017; 35: 347–54. DOI: 10.4103/ijmm.IJMM_16_292
22. Vane JR, Botting RM. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104 (3A): 2S–8S. DOI: 10.1016/S0002-9343(97)00203-9
23. Gagyor I, Bleidorn J, Kochen MM et al. Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial. BMJ 2015; 351: h6544.
24. Bleidorn J, Hummers-Pradier E, Schmie-Mann G et al. Recurrent urinary tract infections and complications after symptomatic versus antibiotic treatment: fol-low-up of a randomised controlled trial. Ger Med Sci 2016; 14: Doc01.
25. Kronenberg A, Butikofer L, Odutayo A et al. Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial. BMJ 2017; 359: j4784. DOI: 10.1136/bmj.j4784
26. Altarac S, Papes D. Use of d-mannose in prophylaxis of recurrent urinary tract infections (UTIs) in women. BJU Int 2014; 113: 9–10.
27. Perrotta C, Aznar M, Mejia R et al. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. Cochrane Database Syst Rev 2008; 2008: CD005131.
28. Hickling DR, Nitti VW. Management of recurrent urinary tract infections in healthy adult women. Rev Urol 2013; 15: 41–8.
29. Simon JA, Altomare C, Cort S et al. Overall safety of ospemifene in postmenopausal women from placebo-controlled phase 2 and 3 trials.
J Womens Health (Larchmt) 2018; 27: 14–23.
30. Carlsson S, Wiklund NP, Engstrand L et al. Effects of pH, nitrite, and ascorbic acid on nonenzymatic nitric oxide generation and bacterial growth in urine. Nitric Oxide 2001; 5: 580–6. DOI: 10.1006/niox.2001.0371
31. Nseir W, Taha M, Nemarny H, Mograbi J. The association between serum levels of Vitamin D and recurrent urinary tract infections in premenopausal women. Int J Infect Dis 2013; 17: e1121–4.
32. Hertting O, Lüthje P, Sullivan D et al. Vitamin D-deficient mice have more invasive urinary tract infection. PLoS One 2017; 12 (7): e0180810. DOI:10.1371/journal.pone.0180810
33. Schmidhammer S, Ramoner R, Holtl L et al. An Escherichia coli-based oral vaccine against urinary tract infections potently activates human dendritic cells. Urology 2002; 60: 521–6. DOI: 10.1016/S0090-4295(02)01767-3
34. Magistro G, Stief CG. Vaccine development for urinary tract infections: wh ere do we stand? Eur Urol Focus 2019; 5: 39–41. DOI: 10.1016/j.euf.2018.07.034
2. Arshad M, Seed PC. Urinary tract infections in the infant. Clin Perinatol 2015; 42 (1): 17–28.
3. Stamm WE, Norrby SR. Urinary tract infections: disease panorama and challenges. J Infect Dis 2001; 183 (Suppl 1.):S1–4.
4. Laurent O.B., Sinyakova L.A., Kosova I.V. Recurrent urinary tract infections. Algorithm for diagnosis and treatment. Moscow: MIA, 2008 (in Russian).
5. Nappi RE, Palacios S. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric 2014; 17 (1): 3–9. DOI: 10.3109/13697137.2013.871696
6. Santajit S, Indrawattana N. Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens. BioMed Res Int 2016; p. 1–8.
7. Eidel'shtein M.V., Sukhorukova M.V., Skleenova E.Iu. et al. Antibiotikorezistentnost' nozokomial'nykh shtammov Pseudomonas aeruginosa v statsionarakh Rossii: rezul'taty mnogotsentrovogo epidemiologicheskogo issledovaniia "Marafon" 2013–2014. Klin. mikrobiologiia i antimikrobnaia khimioterapiia. 2017; 19 (1): 37–41 (in Russian).
8. Kutateladze M, Adamia R. Bacteriophages as Potential New Therapeutics to Replace or Supplement Antibiotics. Trends Biotechnol 2010; 28: 591–5.
9. Miedzybrodzki R, Hoyle N, Zhvaniya F et al. Current Updates fr om the Long-standing Phage Research Centers in Georgia, Poland and Russia. In Bacteriophages; Harper, D., Abedon, S., Burrowes, B., Eds.; Springer: Cham, Switzerland, 2018; p. 1–31.
10. Antibiotic Resistance Threats in the United States; U.S. Department of Health and Human Services, CDC: Atlanta, GA, USA, 2019.
11. Shiriaev A.A., Vasil'ev A.O., Zaitsev A.V. et al. Perspektiva primeneniia bakteriofagov v urologicheskoi praktike. Urologiia. 2019; 6: 131–6 (in Russian).
12. Howell AB, Reed JD, Kreuger CG et al. A-type cranberry proanthocyanidins and uropathogenic bacterial anti- adhesion activity. Phytochemistry 2005; 66: 2281–91. DOI: 10.1016/j.phytochem.2005.05.022
13. Singh I, Gautam LK, Kaur IR. Effect of oral cranberry extract (standardized proanthocyanidin-A) in patients with recurrent UTI by pathogenic E. coli: a randomized placebo-controlled clinical research study. Int Urol Nephrol 2016; 48: 1379–86. DOI: 10.1007/s11255-016-1342-8
14. Vostalova J, Vidlar A, Simanek V et al. Are high proanthocyanidins key to Cranberry efficacy in the prevention of recurrent urinary tract infection? Phytother Res 2015; 29: 1559–67. DOI: 10.1002/ptr.5427
15. Naber KG. Efficacy and safety of the phytotherapeutic drug Canephron N in prevention and treatment of urogenital and gestational disease: review of clinical experience in Eastern Europe and Central Asia. Res Rep Urol 2013; 5: 39–46.
16. Miotla P, Wawrysiuk S, Naber K et al. Should we always use antibiotics after urodynamic studies in high-risk patients? Biomed Res Int 2018; 2018: 1607425. DOI: 10.1155/2018/1607425
17. Wagenlehner FM, Abramov-Sommariva D, Höller M, Steindl H et al. Non-Antibiotic Herbal Therapy (BNO 1045) versus antibiotic therapy (Fosfomycin Trometamol) for the treatment of acute lower uncomplicated urinary tract infections in women: a double-blind, parallel-group, randomized, multicentre non-inferiority phase III trial. Urol Int 2018; 101: 327–36. DOI: 10.1159/000493368
18. Stapleton AE. The vaginal microbiota and urinary tract infection. Microbiol Spectr 2016. DOI: 10.1128/microbiolspec.UTI-0025-2016
19. Beerepoot MA, ter Riet G, Nys S et al. Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in postmenopausal women. Arch Intern Med 2012; 172: 704–12. DOI: 10.1001/archinternmed.2012.777
20. Schwenger EM, Tejani AM, Loewen PS. Probiotics for Preventing Urinary Tract Infections in Adults and Children. Cochrane Database Syst Rev 2015; 12: CD008772. DOI: 10.1002/14651858.CD008772.pub2
21. Gupta V, Nag D, Garg P. Recurrent urinary tract infections in women: how promising is the use of probiotics? Indian J Med Microbiol 2017; 35: 347–54. DOI: 10.4103/ijmm.IJMM_16_292
22. Vane JR, Botting RM. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104 (3A): 2S–8S. DOI: 10.1016/S0002-9343(97)00203-9
23. Gagyor I, Bleidorn J, Kochen MM et al. Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial. BMJ 2015; 351: h6544.
24. Bleidorn J, Hummers-Pradier E, Schmie-Mann G et al. Recurrent urinary tract infections and complications after symptomatic versus antibiotic treatment: fol-low-up of a randomised controlled trial. Ger Med Sci 2016; 14: Doc01.
25. Kronenberg A, Butikofer L, Odutayo A et al. Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial. BMJ 2017; 359: j4784. DOI: 10.1136/bmj.j4784
26. Altarac S, Papes D. Use of d-mannose in prophylaxis of recurrent urinary tract infections (UTIs) in women. BJU Int 2014; 113: 9–10.
27. Perrotta C, Aznar M, Mejia R et al. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. Cochrane Database Syst Rev 2008; 2008: CD005131.
28. Hickling DR, Nitti VW. Management of recurrent urinary tract infections in healthy adult women. Rev Urol 2013; 15: 41–8.
29. Simon JA, Altomare C, Cort S et al. Overall safety of ospemifene in postmenopausal women from placebo-controlled phase 2 and 3 trials. J Womens Health (Larchmt) 2018; 27: 14–23.
30. Carlsson S, Wiklund NP, Engstrand L et al. Effects of pH, nitrite, and ascorbic acid on nonenzymatic nitric oxide generation and bacterial growth in urine. Nitric Oxide 2001; 5: 580–6. DOI: 10.1006/niox.2001.0371
31. Nseir W, Taha M, Nemarny H, Mograbi J. The association between serum levels of Vitamin D and recurrent urinary tract infections in premenopausal women. Int J Infect Dis 2013; 17: e1121–4.
32. Hertting O, Lüthje P, Sullivan D et al. Vitamin D-deficient mice have more invasive urinary tract infection. PLoS One 2017; 12 (7): e0180810. DOI:10.1371/journal.pone.0180810
33. Schmidhammer S, Ramoner R, Holtl L et al. An Escherichia coli-based oral vaccine against urinary tract infections potently activates human dendritic cells. Urology 2002; 60: 521–6. DOI: 10.1016/S0090-4295(02)01767-3
34. Magistro G, Stief CG. Vaccine development for urinary tract infections: wh ere do we stand? Eur Urol Focus 2019; 5: 39–41. DOI: 10.1016/j.euf.2018.07.034
[Kolontarev K.B. Obzor klinicheskikh rekomendatsii po lecheniiu ostroi neoslozhnennoi infektsii nizhnikh mochevykh putei. Effektivnaia farmakoterapiia. 2015; 3: 6–14 (in Russian).]
2. Arshad M, Seed PC. Urinary tract infections in the infant. Clin Perinatol 2015; 42 (1): 17–28.
3. Stamm WE, Norrby SR. Urinary tract infections: disease panorama and challenges. J Infect Dis 2001; 183 (Suppl 1.):S1–4.
4. Лоран О.Б., Синякова Л.А., Косова И.В. Рецидивирующие инфекции мочевых путей. Алгоритм диагностики и лечения. М.: МИА, 2008.
[Laurent O.B., Sinyakova L.A., Kosova I.V. Recurrent urinary tract infections. Algorithm for diagnosis and treatment. Moscow: MIA, 2008 (in Russian).]
5. Nappi RE, Palacios S. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric 2014; 17 (1): 3–9. DOI:10.3109/13697137.2013.871696
6. Santajit S, Indrawattana N. Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens. BioMed Res Int 2016; p. 1–8.
7. Эйдельштейн М.В., Сухорукова М.В., Склеенова Е.Ю. и др. Антибиотикорезистентность нозокомиальных штаммов Pseudomonas aeruginosa в стационарах России: результаты многоцентрового эпидемиологического исследования «Марафон» 2013–2014. Клин. микробиология и антимикробная химиотерапия. 2017; 19 (1): 37–41.
[Eidel'shtein M.V., Sukhorukova M.V., Skleenova E.Iu. et al. Antibiotikorezistentnost' nozokomial'nykh shtammov Pseudomonas aeruginosa v statsionarakh Rossii: rezul'taty mnogotsentrovogo epidemiologicheskogo issledovaniia "Marafon" 2013–2014. Klin. mikrobiologiia i antimikrobnaia khimioterapiia. 2017; 19 (1): 37–41 (in Russian).]
8. Kutateladze M, Adamia R. Bacteriophages as Potential New Therapeutics to Replace or Supplement Antibiotics. Trends Biotechnol 2010; 28: 591–5.
9. Miedzybrodzki R, Hoyle N, Zhvaniya F et al. Current Updates fr om the Long-standing Phage Research Centers in Georgia, Poland and Russia. In Bacteriophages; Harper, D., Abedon, S., Burrowes, B., Eds.; Springer: Cham, Switzerland, 2018; p. 1–31.
10. Antibiotic Resistance Threats in the United States; U.S. Department of Health and Human Services, CDC: Atlanta, GA, USA, 2019.
11. Ширяев А.А., Васильев А.О., Зайцев А.В. и др. Перспектива применения бактериофагов в урологической практике. Урология. 2019; 6: 131–6.
[Shiriaev A.A., Vasil'ev A.O., Zaitsev A.V. et al. Perspektiva primeneniia bakteriofagov v urologicheskoi praktike. Urologiia. 2019; 6: 131–6 (in Russian).]
12. Howell AB, Reed JD, Kreuger CG et al. A-type cranberry proanthocyanidins and uropathogenic bacterial anti- adhesion activity. Phytochemistry 2005; 66: 2281–91. DOI: 10.1016/j.phytochem.2005.05.022
13. Singh I, Gautam LK, Kaur IR. Effect of oral cranberry extract (standardized proanthocyanidin-A) in patients with recurrent UTI by pathogenic E. coli: a randomized placebo-controlled clinical research study. Int Urol Nephrol 2016; 48: 1379–86. DOI: 10.1007/s11255-016-1342-8
14. Vostalova J, Vidlar A, Simanek V et al. Are high proanthocyanidins key to Cranberry efficacy in the prevention of recurrent urinary tract infection? Phytother Res 2015; 29: 1559–67. DOI: 10.1002/ptr.5427
15. Naber KG. Efficacy and safety of the phytotherapeutic drug Canephron N in prevention and treatment of urogenital and gestational disease: review of clinical experience in Eastern Europe and Central Asia. Res Rep Urol 2013; 5: 39–46.
16. Miotla P, Wawrysiuk S, Naber K et al. Should we always use antibiotics after urodynamic studies in high-risk patients? Biomed Res Int 2018; 2018: 1607425. DOI: 10.1155/2018/1607425
17. Wagenlehner FM, Abramov-Sommariva D, Höller M, Steindl H et al. Non-Antibiotic Herbal Therapy (BNO 1045) versus antibiotic therapy (Fosfomycin Trometamol) for the treatment of acute lower uncomplicated urinary tract infections in women: a double-blind, parallel-group, randomized, multicentre non-inferiority phase III trial. Urol Int 2018; 101: 327–36. DOI: 10.1159/000493368
18. Stapleton AE. The vaginal microbiota and urinary tract infection. Microbiol Spectr 2016. DOI: 10.1128/microbiolspec.UTI-0025-2016
19. Beerepoot MA, ter Riet G, Nys S et al. Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in postmenopausal women. Arch Intern Med 2012; 172: 704–12. DOI: 10.1001/archinternmed.2012.777
20. Schwenger EM, Tejani AM, Loewen PS. Probiotics for Preventing Urinary Tract Infections in Adults and Children. Cochrane Database Syst Rev 2015; 12: CD008772. DOI: 10.1002/14651858.CD008772.pub2
21. Gupta V, Nag D, Garg P. Recurrent urinary tract infections in women: how promising is the use of probiotics? Indian J Med Microbiol 2017; 35: 347–54. DOI: 10.4103/ijmm.IJMM_16_292
22. Vane JR, Botting RM. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104 (3A): 2S–8S. DOI: 10.1016/S0002-9343(97)00203-9
23. Gagyor I, Bleidorn J, Kochen MM et al. Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial. BMJ 2015; 351: h6544.
24. Bleidorn J, Hummers-Pradier E, Schmie-Mann G et al. Recurrent urinary tract infections and complications after symptomatic versus antibiotic treatment: fol-low-up of a randomised controlled trial. Ger Med Sci 2016; 14: Doc01.
25. Kronenberg A, Butikofer L, Odutayo A et al. Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial. BMJ 2017; 359: j4784. DOI: 10.1136/bmj.j4784
26. Altarac S, Papes D. Use of d-mannose in prophylaxis of recurrent urinary tract infections (UTIs) in women. BJU Int 2014; 113: 9–10.
27. Perrotta C, Aznar M, Mejia R et al. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. Cochrane Database Syst Rev 2008; 2008: CD005131.
28. Hickling DR, Nitti VW. Management of recurrent urinary tract infections in healthy adult women. Rev Urol 2013; 15: 41–8.
29. Simon JA, Altomare C, Cort S et al. Overall safety of ospemifene in postmenopausal women from placebo-controlled phase 2 and 3 trials.
J Womens Health (Larchmt) 2018; 27: 14–23.
30. Carlsson S, Wiklund NP, Engstrand L et al. Effects of pH, nitrite, and ascorbic acid on nonenzymatic nitric oxide generation and bacterial growth in urine. Nitric Oxide 2001; 5: 580–6. DOI: 10.1006/niox.2001.0371
31. Nseir W, Taha M, Nemarny H, Mograbi J. The association between serum levels of Vitamin D and recurrent urinary tract infections in premenopausal women. Int J Infect Dis 2013; 17: e1121–4.
32. Hertting O, Lüthje P, Sullivan D et al. Vitamin D-deficient mice have more invasive urinary tract infection. PLoS One 2017; 12 (7): e0180810. DOI:10.1371/journal.pone.0180810
33. Schmidhammer S, Ramoner R, Holtl L et al. An Escherichia coli-based oral vaccine against urinary tract infections potently activates human dendritic cells. Urology 2002; 60: 521–6. DOI: 10.1016/S0090-4295(02)01767-3
34. Magistro G, Stief CG. Vaccine development for urinary tract infections: wh ere do we stand? Eur Urol Focus 2019; 5: 39–41. DOI: 10.1016/j.euf.2018.07.034
________________________________________________
2. Arshad M, Seed PC. Urinary tract infections in the infant. Clin Perinatol 2015; 42 (1): 17–28.
3. Stamm WE, Norrby SR. Urinary tract infections: disease panorama and challenges. J Infect Dis 2001; 183 (Suppl 1.):S1–4.
4. Laurent O.B., Sinyakova L.A., Kosova I.V. Recurrent urinary tract infections. Algorithm for diagnosis and treatment. Moscow: MIA, 2008 (in Russian).
5. Nappi RE, Palacios S. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric 2014; 17 (1): 3–9. DOI: 10.3109/13697137.2013.871696
6. Santajit S, Indrawattana N. Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens. BioMed Res Int 2016; p. 1–8.
7. Eidel'shtein M.V., Sukhorukova M.V., Skleenova E.Iu. et al. Antibiotikorezistentnost' nozokomial'nykh shtammov Pseudomonas aeruginosa v statsionarakh Rossii: rezul'taty mnogotsentrovogo epidemiologicheskogo issledovaniia "Marafon" 2013–2014. Klin. mikrobiologiia i antimikrobnaia khimioterapiia. 2017; 19 (1): 37–41 (in Russian).
8. Kutateladze M, Adamia R. Bacteriophages as Potential New Therapeutics to Replace or Supplement Antibiotics. Trends Biotechnol 2010; 28: 591–5.
9. Miedzybrodzki R, Hoyle N, Zhvaniya F et al. Current Updates fr om the Long-standing Phage Research Centers in Georgia, Poland and Russia. In Bacteriophages; Harper, D., Abedon, S., Burrowes, B., Eds.; Springer: Cham, Switzerland, 2018; p. 1–31.
10. Antibiotic Resistance Threats in the United States; U.S. Department of Health and Human Services, CDC: Atlanta, GA, USA, 2019.
11. Shiriaev A.A., Vasil'ev A.O., Zaitsev A.V. et al. Perspektiva primeneniia bakteriofagov v urologicheskoi praktike. Urologiia. 2019; 6: 131–6 (in Russian).
12. Howell AB, Reed JD, Kreuger CG et al. A-type cranberry proanthocyanidins and uropathogenic bacterial anti- adhesion activity. Phytochemistry 2005; 66: 2281–91. DOI: 10.1016/j.phytochem.2005.05.022
13. Singh I, Gautam LK, Kaur IR. Effect of oral cranberry extract (standardized proanthocyanidin-A) in patients with recurrent UTI by pathogenic E. coli: a randomized placebo-controlled clinical research study. Int Urol Nephrol 2016; 48: 1379–86. DOI: 10.1007/s11255-016-1342-8
14. Vostalova J, Vidlar A, Simanek V et al. Are high proanthocyanidins key to Cranberry efficacy in the prevention of recurrent urinary tract infection? Phytother Res 2015; 29: 1559–67. DOI: 10.1002/ptr.5427
15. Naber KG. Efficacy and safety of the phytotherapeutic drug Canephron N in prevention and treatment of urogenital and gestational disease: review of clinical experience in Eastern Europe and Central Asia. Res Rep Urol 2013; 5: 39–46.
16. Miotla P, Wawrysiuk S, Naber K et al. Should we always use antibiotics after urodynamic studies in high-risk patients? Biomed Res Int 2018; 2018: 1607425. DOI: 10.1155/2018/1607425
17. Wagenlehner FM, Abramov-Sommariva D, Höller M, Steindl H et al. Non-Antibiotic Herbal Therapy (BNO 1045) versus antibiotic therapy (Fosfomycin Trometamol) for the treatment of acute lower uncomplicated urinary tract infections in women: a double-blind, parallel-group, randomized, multicentre non-inferiority phase III trial. Urol Int 2018; 101: 327–36. DOI: 10.1159/000493368
18. Stapleton AE. The vaginal microbiota and urinary tract infection. Microbiol Spectr 2016. DOI: 10.1128/microbiolspec.UTI-0025-2016
19. Beerepoot MA, ter Riet G, Nys S et al. Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in postmenopausal women. Arch Intern Med 2012; 172: 704–12. DOI: 10.1001/archinternmed.2012.777
20. Schwenger EM, Tejani AM, Loewen PS. Probiotics for Preventing Urinary Tract Infections in Adults and Children. Cochrane Database Syst Rev 2015; 12: CD008772. DOI: 10.1002/14651858.CD008772.pub2
21. Gupta V, Nag D, Garg P. Recurrent urinary tract infections in women: how promising is the use of probiotics? Indian J Med Microbiol 2017; 35: 347–54. DOI: 10.4103/ijmm.IJMM_16_292
22. Vane JR, Botting RM. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104 (3A): 2S–8S. DOI: 10.1016/S0002-9343(97)00203-9
23. Gagyor I, Bleidorn J, Kochen MM et al. Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial. BMJ 2015; 351: h6544.
24. Bleidorn J, Hummers-Pradier E, Schmie-Mann G et al. Recurrent urinary tract infections and complications after symptomatic versus antibiotic treatment: fol-low-up of a randomised controlled trial. Ger Med Sci 2016; 14: Doc01.
25. Kronenberg A, Butikofer L, Odutayo A et al. Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial. BMJ 2017; 359: j4784. DOI: 10.1136/bmj.j4784
26. Altarac S, Papes D. Use of d-mannose in prophylaxis of recurrent urinary tract infections (UTIs) in women. BJU Int 2014; 113: 9–10.
27. Perrotta C, Aznar M, Mejia R et al. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. Cochrane Database Syst Rev 2008; 2008: CD005131.
28. Hickling DR, Nitti VW. Management of recurrent urinary tract infections in healthy adult women. Rev Urol 2013; 15: 41–8.
29. Simon JA, Altomare C, Cort S et al. Overall safety of ospemifene in postmenopausal women from placebo-controlled phase 2 and 3 trials. J Womens Health (Larchmt) 2018; 27: 14–23.
30. Carlsson S, Wiklund NP, Engstrand L et al. Effects of pH, nitrite, and ascorbic acid on nonenzymatic nitric oxide generation and bacterial growth in urine. Nitric Oxide 2001; 5: 580–6. DOI: 10.1006/niox.2001.0371
31. Nseir W, Taha M, Nemarny H, Mograbi J. The association between serum levels of Vitamin D and recurrent urinary tract infections in premenopausal women. Int J Infect Dis 2013; 17: e1121–4.
32. Hertting O, Lüthje P, Sullivan D et al. Vitamin D-deficient mice have more invasive urinary tract infection. PLoS One 2017; 12 (7): e0180810. DOI:10.1371/journal.pone.0180810
33. Schmidhammer S, Ramoner R, Holtl L et al. An Escherichia coli-based oral vaccine against urinary tract infections potently activates human dendritic cells. Urology 2002; 60: 521–6. DOI: 10.1016/S0090-4295(02)01767-3
34. Magistro G, Stief CG. Vaccine development for urinary tract infections: wh ere do we stand? Eur Urol Focus 2019; 5: 39–41. DOI: 10.1016/j.euf.2018.07.034
Авторы
А.О. Васильев*1–3, Н.А. Сазонова1, В.Д. Мельников1, А.Ф. Габдуллин1, А.В. Зайцев1,3, А.А. Ширяев1,3, Ю.А. Ким1,3, Е.А. Прилепская1,3, Д.Ю. Пушкарь1,3
1 ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России, Москва, Россия;
2 ГБУ «Научно-исследовательский институт организации здравоохранения и медицинского менеджмента» Департамента здравоохранения г. Москвы, Москва, Россия;
3 ГБУЗ «Городская клиническая больница им. С.И. Спасокукоцкого» Департамента здравоохранения г. Москвы, Москва, Россия
*kalinina@outlook.com
1 Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia;
2 Research Institute of Health Organization and Medical Management, Moscow, Russia;
3 Spasokukotsky City Clinical Hospital, Moscow, Russia
*kalinina@outlook.com
1 ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России, Москва, Россия;
2 ГБУ «Научно-исследовательский институт организации здравоохранения и медицинского менеджмента» Департамента здравоохранения г. Москвы, Москва, Россия;
3 ГБУЗ «Городская клиническая больница им. С.И. Спасокукоцкого» Департамента здравоохранения г. Москвы, Москва, Россия
*kalinina@outlook.com
________________________________________________
1 Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia;
2 Research Institute of Health Organization and Medical Management, Moscow, Russia;
3 Spasokukotsky City Clinical Hospital, Moscow, Russia
*kalinina@outlook.com
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.